Collectively, these data suggest that the overexpression of the protein might be a relatively early step in the process of tumorigenesis; hence, the determination of RasGRP3 levels in breast cancer tissues may hold promise for the benefits of early diagnosis and may offer suitable target for treatment of breast tumors. This evidence concerns the gene RASGRP3 and breast neoplasm.